B019

Phase 1Biologic

SShanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.

B019 is one of 2 biologic programs targeting Relapsed or Refractory B Cell Non-Hodgkin Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed or Refractory B Cell Non-Hodgkin LymphomaNot yet recruiting

Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaRecruiting

Relapsed or Refractory B Cell Non-Hodgkin LymphomaPhase 1

Not yet recruiting

Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaPhase 1

Recruiting

Competition

Competitive Landscape

1 competitor in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

#DrugCompanyPhaseTrials

B019

SShanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.

Phase 1

1 2

AUTO1

AAutolus Limited

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

NCT06970496

Q2 2028

Phase 1Recruiting

Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

NCT06927466

Clinical

Trials by Indication[1]

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia1 trial

A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.

Recruiting·SShanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.·Phase 1·NCT06927466·33 enrolled

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma1 trial

A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.

Not yet recruiting·SShanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.·Phase 1·NCT06970496·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for B019. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — B019 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for B019. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SShanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.

B019

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Trials by Indication[1]

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia1 trial

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News